Innovation Pharmaceuticals Inc (IPIX)

[DaubersUP]

B-UP Interim Data Here:

http://www.ipharminc.com/press-release/2017/3/19/cellceutix-releases-favorable-topline-findings-as-part-of-interim-analysis-of-phase-2-drug-candidate-brilacidin-for-the-treatment-of-inflammatory-bowel-disease

Patient Quality of Life (as assessed by the Short Inflammatory Bowel Disease Questionnaire, SIBDQ)—notable improvements in all 12 patients; 50 percent of patients in Cohort A (3 of 6) and 80 percent of patients in Cohort B (5 of 6) reported significant improvements of 15 points to more than 50 points higher on the 70-point SIBDQ scale.